Precise thrombolysis in-vivo and in-vitro study on improved MnO2-loaded pep'-Fuco nanocarriers

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cardiovascular Research

Background:

• Venous thrombosis is a major global cause of cardiovascular disease mortality.
• Current thrombolytic therapies have limitations including systemic side effects and poor targeting.
• Hypoxic microenvironments within thrombi can reduce the effectiveness of existing treatments.

Purpose of the Study:

• To evaluate the thrombolytic efficacy of MnO2@pep'-Fuco nanoparticles for venous thrombosis.
• To assess the performance of these nanoparticles in both in vitro and in vivo models.

Main Methods:

• Rats were treated with various formulations including PBS, MnO2@pep-Fuco, free urokinase plasminogen activator (uPA), and different MnO2/uPA@pep-Fuco constructs.
• Key parameters measured included vascular occlusion rate, hemolysis, body weight, and plasma biochemical profiles.

Main Results:

• MnO2@pep'-Fuco nanoparticles demonstrated a high pep-Fuco grafting rate (3.87%) and efficient oxygen/drug release.
• In vivo studies achieved complete thrombolysis (100%) with excellent biocompatibility and biosafety.
• Low hemolysis rates (0.65-0.82%) and no significant changes in body weight were observed.

Conclusions:

• The MnO2/uPA@pep-Fuco nanoparticle system represents a highly effective novel therapeutic strategy.
• This targeted approach shows significant potential for treating venous thrombosis.
• The nanoparticles offer improved efficacy and safety compared to conventional thrombolytic methods.